Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer
February 10, 2022 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program
December 14, 2021 06:30 ET
|
Generation Bio Co.
Innovations in closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) production processes generated peak mean of 205% normal human factor VIII expression in miceNon-human primates...
Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results
November 10, 2021 16:20 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery of ceDNA and mRNA at the European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
October 22, 2021 07:30 ET
|
Generation Bio Co.
Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) demonstrated broad photoreceptor distribution, durable expression and tolerability in rodents;...
Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit
October 21, 2021 16:05 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
October 15, 2021 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today...
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results
August 11, 2021 16:20 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021
August 03, 2021 07:30 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
July 14, 2021 07:30 ET
|
Generation Bio Co.
Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing Lease agreement signed to build an...